SCHEMBL25517535

SCHEMBL25517535

CC(=O)OC(C)c1ccc(C)nc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
LMNA P02545 3/20 0.37
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP17A1 P05093 2/20 0.36
CYP19A1 P11511 2/20 0.36
TSHR P16473 2/20 0.35
OPRK1 P41145 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP3A4 P08684 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ABCB11 O95342 1/20 0.35
ESR1 P03372 1/20 0.35
ADRA2A P08913 1/20 0.35
CYP2C9 P11712 1/20 0.35
PDE4A P27815 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20719609 0.81 FDFT1 (0.34) LMNAMAPTCYP17A1CYP19A1TSHR
SCHEMBL26156221 0.78 CYP2C9 (0.40) P2RX7CYP3A4CYP2C9
SCHEMBL20719575 0.78 AR (0.36) LMNATSHROPRK1CYP3A4KDM4E
Hydrochloric Acid SCHEMBL20719483 0.76 ESR1 (0.35) LMNAMAPTCYP17A1CYP19A1TSHR
SCHEMBL27558665 0.76 CYP17A1 (0.58) LMNASMN1; SMN2CYP17A1CYP19A1KDM4E
SCHEMBL13777889 0.76 LMNA (0.47) LMNAMAPTSMN1; SMN2TSHRCYP3A4
SCHEMBL31607962 0.76 LMNA (0.47) LMNAMAPTSMN1; SMN2TSHRCYP3A4
SCHEMBL10663681 0.74 MAPT (0.37) P2RX7HDAC1HDAC6LMNANPC1
SCHEMBL20719768 0.74 GABRG2 (0.40)
SCHEMBL27654524 0.74 HDAC1 (0.43) P2RX7HDAC1HDAC6LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 US disclosed
CN-101287738-B Imidazo benzodiazepine derivatives HOFFMANN LA ROCHE 2011-08-10 CN disclosed
CN-101287738-A Imidazo benzodiazepine derivatives HOFFMANN LA ROCHE (CH) 2008-10-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF SSB, EBNA1BP2, PML P2RX7 3819/4885HDAC1 346/4885HDAC6 1179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.